[{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2022","type":"Inapplicable","leadProduct":"Imiquimod","moa":"||Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"The University of Texas MD Anderson Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody, Unconjugated","year":"2021","type":"Collaboration","leadProduct":"Imiquimod","moa":"||Cytotoxic T-lymphocyte protein 4","graph1":"Oncology","graph2":"IND Enabling","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Solution","sponsorNew":"UroGen Pharma \/ The University of Texas MD Anderson Cancer Center","highestDevelopmentStatusID":"5","companyTruncated":"UroGen Pharma \/ The University of Texas MD Anderson Cancer Center"},{"orgOrder":0,"company":"UroGen Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase II","graph3":"UroGen Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"UroGen Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"UroGen Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Nantes University Hospital","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"FRANCE","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase III","graph3":"Nantes University Hospital","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Nantes University Hospital \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Nantes University Hospital \/ Viatris"},{"orgOrder":0,"company":"Maastricht University Medical Center","sponsor":"Viatris","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NETHERLANDS","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase III","graph3":"Maastricht University Medical Center","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Cream","sponsorNew":"Maastricht University Medical Center \/ Viatris","highestDevelopmentStatusID":"10","companyTruncated":"Maastricht University Medical Center \/ Viatris"},{"orgOrder":0,"company":"Melanoma and Skin Cancer Trials Limited","sponsor":"Melanoma Institute Australia","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase III","graph3":"Melanoma and Skin Cancer Trials Limited","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Melanoma and Skin Cancer Trials Limited \/ Melanoma Institute Australia","highestDevelopmentStatusID":"10","companyTruncated":"Melanoma and Skin Cancer Trials Limited \/ Melanoma Institute Australia"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Actavis Inc","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"IRELAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase III","graph3":"Actavis Inc","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Actavis Inc \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Actavis Inc \/ Undisclosed"},{"orgOrder":0,"company":"Teva Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"ISRAEL","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase III","graph3":"Teva Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Teva Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Teva Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"AIDS Malignancy Consortium","sponsor":"National Cancer Institute | The Emmes Company, LLC | University of Arkansas","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase III","graph3":"AIDS Malignancy Consortium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIDS Malignancy Consortium \/ National Cancer Institute | The Emmes Company, LLC | University of Arkansas","highestDevelopmentStatusID":"10","companyTruncated":"AIDS Malignancy Consortium \/ National Cancer Institute | The Emmes Company, LLC | University of Arkansas"},{"orgOrder":0,"company":"AIDS Malignancy Consortium","sponsor":"National Cancer Institute | The Emmes Company, LLC | University of Arkansas | University of California, San Francisco | University of Arizona","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase III","graph3":"AIDS Malignancy Consortium","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AIDS Malignancy Consortium \/ National Cancer Institute | The Emmes Company, LLC | University of Arkansas | University of California, San Francisco | University of Arizona","highestDevelopmentStatusID":"10","companyTruncated":"AIDS Malignancy Consortium \/ National Cancer Institute | The Emmes Company, LLC | University of Arkansas | University of California, San Francisco | University of Arizona"},{"orgOrder":0,"company":"Icahn School of Medicine at Mount Sinai","sponsor":"Bausch Health","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase II","graph3":"Icahn School of Medicine at Mount Sinai","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Icahn School of Medicine at Mount Sinai \/ Bausch Health","highestDevelopmentStatusID":"8","companyTruncated":"Icahn School of Medicine at Mount Sinai \/ Bausch Health"},{"orgOrder":0,"company":"MEDICIS","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase IV","graph3":"MEDICIS","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"MEDICIS \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"MEDICIS \/ Undisclosed"},{"orgOrder":0,"company":"Taro Pharmaceutical Industries","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase I","graph3":"Taro Pharmaceutical Industries","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Taro Pharmaceutical Industries \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Taro Pharmaceutical Industries \/ Undisclosed"},{"orgOrder":0,"company":"Washington University School of Medicine","sponsor":"Merck & Co","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase I","graph3":"Washington University School of Medicine","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Washington University School of Medicine \/ Merck & Co","highestDevelopmentStatusID":"6","companyTruncated":"Washington University School of Medicine \/ Merck & Co"},{"orgOrder":0,"company":"Viatris","sponsor":"SIRO Clinpharm | Accovion","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase IV","graph3":"Viatris","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Sachet","sponsorNew":"Viatris \/ SIRO Clinpharm | Accovion","highestDevelopmentStatusID":"11","companyTruncated":"Viatris \/ SIRO Clinpharm | Accovion"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase II","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Undisclosed","graph2":"Phase I","graph3":"Moberg Pharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Moberg Pharma \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Moberg Pharma \/ Undisclosed"},{"orgOrder":0,"company":"Barretos Cancer Hospital","sponsor":"Farmoquimica","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BRAZIL","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase II","graph3":"Barretos Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Barretos Cancer Hospital \/ Farmoquimica","highestDevelopmentStatusID":"8","companyTruncated":"Barretos Cancer Hospital \/ Farmoquimica"},{"orgOrder":0,"company":"Barretos Cancer Hospital","sponsor":"FAPESP | Farmoquimica | Hospital de Cancer de Barretos - Fundacao Pio XII","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"BRAZIL","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Oncology","graph2":"Phase IV","graph3":"Barretos Cancer Hospital","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Barretos Cancer Hospital \/ FAPESP | Farmoquimica | Hospital de Cancer de Barretos - Fundacao Pio XII","highestDevelopmentStatusID":"11","companyTruncated":"Barretos Cancer Hospital \/ FAPESP | Farmoquimica | Hospital de Cancer de Barretos - Fundacao Pio XII"},{"orgOrder":0,"company":"Amylynne Frankel","sponsor":"Graceway Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Imiquimod","moa":"Toll-like receptor 7","graph1":"Dermatology","graph2":"Phase IV","graph3":"Amylynne Frankel","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amylynne Frankel \/ Graceway Pharmaceuticals","highestDevelopmentStatusID":"11","companyTruncated":"Amylynne Frankel \/ Graceway Pharmaceuticals"},{"orgOrder":0,"company":"CARE","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Imiquimod","moa":"||Toll-like receptor 7","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"CARE","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"CARE \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"CARE \/ Undisclosed"}]
Find Clinical Drug Pipeline Developments & Deals for Imiquimod
Details :
Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Squamous Intraepithelial Lesions.
Details :
Submission of an IND application to U.S. FDA in support of the planned initiation of Phase I clinical study for its anti-CTLA4 antibody, UGN-301 (zalifrelimab), investigational immunotherapy designed for monotherapy and combination therapy in treating lo...
Details :
The collaboration aims to advance combinatorial intravesical immunotherapy, UGN-201 (imiquimod), a TLR 7/8 agonist and UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, for the treatment of HG-NMIBC.
Details :
Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Breast Neoplasms.
Details :
Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Keratosis, Actinic.
Details :
Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Intraepithelial Neoplasia.
Details :
Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Hutchinson's Melanotic Freckle.
Details :
Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Uterine Cervical Dysplasia.
Sponsor :
National Cancer Institute | The Emmes Company, LLC | University of Arkansas | University of California, San Francisco | University of Arizona
Details :
Imiquimod is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Anus Neoplasms.
Sponsor :
National Cancer Institute | The Emmes Company, LLC | University of Arkansas | University of California, San Francisco | University of Arizona